Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H22FNO3 |
| Molecular Weight | 403.4455 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H]1C[C@H](OC(=O)C1)\C=C\C2=C(C3=CC=C(F)C=C3)C4=CC=CC=C4N=C2C5CC5
InChI
InChIKey=XJVKVAFYQRWVAJ-MCBHFWOFSA-N
InChI=1S/C25H22FNO3/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-19-13-18(28)14-23(29)30-19/h1-4,7-12,16,18-19,28H,5-6,13-14H2/b12-11+/t18-,19-/m1/s1
| Molecular Formula | C25H22FNO3 |
| Molecular Weight | 403.4455 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Pitavastatin lactone is the major metabolite of pitavastatin in humans. Pitavastatin is a potent competitive inhibitor of HMG-CoA reductase, which is indicated for hypercholesterolaemia (elevated cholesterol) and for the prevention of cardiovascular disease. Uridine 5’ -diphosphate (UDP) glucuronosyl transferase (UGT) is critically involved in the lactonization of pitavastatin in man and animals. The metabolic and transporter profiles of pitavastatin in man are complex, involving acid/lactone interconversion. Both forms of pitavastatin are observed in-vivo following oral administration. Lactone form and pitavastatin differ in substrate activity towards uptake and efflux transporters.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Interaction between several medicines and statins. | 2003 |
|
| Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans. | 2003 Jul |
|
| Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. | 2004 Nov-Dec |
|
| Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. | 2005 Mar |
|
| Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. | 2005 Oct |
|
| Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. | 2005 Oct |
Patents
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:38:53 GMT 2023
by
admin
on
Sat Dec 16 08:38:53 GMT 2023
|
| Record UNII |
ULK88EV7VQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ULK88EV7VQ
Created by
admin on Sat Dec 16 08:38:53 GMT 2023 , Edited by admin on Sat Dec 16 08:38:53 GMT 2023
|
PRIMARY | |||
|
141750-63-2
Created by
admin on Sat Dec 16 08:38:53 GMT 2023 , Edited by admin on Sat Dec 16 08:38:53 GMT 2023
|
PRIMARY | |||
|
m8891
Created by
admin on Sat Dec 16 08:38:53 GMT 2023 , Edited by admin on Sat Dec 16 08:38:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
9801294
Created by
admin on Sat Dec 16 08:38:53 GMT 2023 , Edited by admin on Sat Dec 16 08:38:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
FECAL
|
||
|
PARENT -> METABOLITE |
MAJOR
PLASMA
|
||
|
PARENT -> METABOLITE |
URINE
|
